All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable Disease-modifying Therapy (DMT) for Relapsing Multiple Sclerosis in Germany. Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to approx. two years of treatment. Additionally, medical history of participants will be collected including disease duration, EDSS, MRI parameters and relapses.
Relapsing Multiple Sclerosis
May 10, 2022
Oct 17, 2025
18 Years - 100 Years (Adult, Older Adult)
There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.
There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.
There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled.
Signed informed consent must be obtained prior to participation in the study
Male or female patients aged ≥18 years at enrollment
Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018b)
RMS with active disease as defined by Lublin et al. (2014)
Max. 1 relapse during the previous year or max. 2 relapses during the previous two years prior to enrollment
Disability status at enrollment with an EDSS score of 0 to 2.5 (inclusive)
Planned initiation or initiation within the past 14 days with an approved injectable DMT for MS as routine medical treatment
Patients being treated outside of the approved label
>3 years since first symptom(s) (leading to MS diagnosis) at enrollment
Previous therapy with any DMT for the treatment of MS prior to enrollment (except within the past 14 days with an approved injectable DMT for MS as routine medical treatment; see Inclusion criteria #7)
Relapse prior to enrollment which has led to a severe deficit relevant to everyday life upon discretion of the investigator after exhaustion of the relapse therapy
Poor recovery from the first two relapses prior to enrollment upon discretion of the investigator
EDSS Functional System Score "Pyramidal Functions" ≥ 2 at enrollment
Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab